Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma
Cell Signaling Technology, Inc.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2007/001360, filed Jan 19, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,099,188 | Ros Kinase in Lung Cancer In force · Medium confidence UsedRemaining | Cell Signaling Technology, Inc. | In force | Medium confidence | ||
| US 11,761,005 | Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma In force · High confidence | Cell Signaling Technology, Inc. | In force | High confidence | ||
| US 9,328,349 | Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma In force · Medium confidence | Cell Signaling Technology, Inc. | In force | Medium confidence | ||
| US 10,526,661 | Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma In force · Medium confidence | Cell Signaling Technology, Inc. | In force | Medium confidence | ||
| US 8,383,799 | Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma In force · High confidence | Cell Signaling Technology, Inc. | In force | High confidence | ||
| US 9,539,254 | Mutant ROS Expression In Human Cancer In force · High confidence | Cell Signaling Technology, Inc. | In force | High confidence | ||
| US 9,364,477 | Mutant ROS Expression In Human Cancer In force · High confidence | Cell Signaling Technology, Inc. | In force | High confidence | ||
| Application 12/581,126 | Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma Abandoned Abandoned Feb 21, 2013 | Cell Signaling Technology, Inc. | Abandoned | Abandoned Feb 21, 2013 | ||
| Application 13/113,676 | ROS Kinase in Lung Cancer Abandoned Abandoned Jun 7, 2018 | Cell Signaling Technology, Inc. | Abandoned | Abandoned Jun 7, 2018 | ||
| Application 13/632,673 | Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma Abandoned Abandoned Apr 13, 2016 | Cell Signaling Technology, Inc. | Abandoned | Abandoned Apr 13, 2016 | ||
| 4 more records in this group · Pro | ||||||
10 of 14 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 14, including 2 expiring within the 18 months from Nov 19, 2026.
7 of these are in force and held by Cell Signaling Technology, Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.